好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Randomized Phase 2B trial of NP001, a Novel Immune Regulator, in ALS
Neuromuscular and Clinical Neurophysiology (EMG)
S38 - (-)
004
Authors/Disclosures
Robert G. Miller, MD (Dept Of Neurology, CA Pacific)
PRESENTER
The institution of Dr. Miller has received research support from Nurown.
Jonathan S. Katz, MD (CPMC) Dr. Katz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Griffols. Dr. Katz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Katz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dianthus. Dr. Katz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Katz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kedrion. Dr. Katz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Katz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Griffols.
Gilbert A. Block, MD, PhD (The Willmatt Group) No disclosure on file
No disclosure on file